Generic Name and Formulations:
Fluvastatin sodium 20mg, 40mg; caps.
Novartis Pharmaceuticals Corp
Indications for LESCOL:
Adjunct to diet in primary hypercholesterolemia and mixed dyslipidemia (Types IIa and IIb) to reduce elevated total-C, LDL-C, TG, and apo B, and to increase HDL-C when response to nondrug therapy is inadequate. Adjunct to diet to reduce total-C, LDL-C and apo B in patients 10–16 years of age (≥1 year post-menarche) with heterozygous familial hypercholesterolemia if LDL-C remains ≥190mg/dL, or if LDL-C remains ≥160mg/dL with either family history of premature cardiovascular disease (CVD) or if patient has at least 2 other CVD risk factors. In patients with coronary heart disease: To slow the progression of coronary atherosclerosis to lower total-C and LDL-C, and to reduce the risk of undergoing coronary revascularization procedures. Limitations of Use: not studied in conditions where major abnormality is elevation of chylomicrons, VLDL, or IDL.
Swallow whole. ≥18yrs: LDL-C reduction of <25%: initially Lescol 20mg capsule once daily in the PM. LDL-C reduction of ≥25%: Lescol XL 80mg tab once daily, or Lescol 40mg capsule once daily in the PM or twice daily. Usual range: 20–80mg/day. Concomitant cyclosporine, fluconazole: max Lescol 20mg capsule twice daily.
<10yrs: not recommended. 10–16yrs: Initially Lescol 20mg capsule once daily; may increase dose at 6-week intervals to max daily dose of either Lescol 40mg capsule twice daily or Lescol XL 80mg tablet once daily.
Active liver disease. Unexplained, persistent elevated serum transaminases. Pregnancy (Cat.X). Nursing mothers.
Discontinue if myopathy, elevated CPK levels occur; suspend if a predisposition to development of renal failure secondary to rhabdomyolysis develops. Monitor liver function before starting therapy and repeat as clinically indicated. Interrupt therapy if serious liver injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs; do not restart if alternate etiology not found. History of liver disease. Substantial alcohol consumption. Monitor for endocrine dysfunction. Homozygous familial hypercholesterolemia. Severe renal insufficiency.
See Adult dose. Avoid concomitant gemfibrozil. Caution with other fibrates, niacin (≥1g/day), colchicine; consider reducing dose of fluvastatin. Monitor oral anticoagulants, glyburide, phenytoin. Inhibition of endogenous steroid production with spironolactone, ketoconazole, cimetidine.
HMG-CoA reductase inhibitor.
Headache, dyspepsia, myalgia, abdominal pain, nausea, elevated serum transaminases, myopathy, rhabdomyolysis with renal dysfunction; increased HbA1c and fasting serum glucose, rare: cognitive impairment, non-fatal hepatic failure, immune-mediated
Tabs, caps—30, 100
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Adjunctive Therapies for Bipolar Disorder Show Promise, Need More Evidence
- Predicting Treatment-Emergent Mania to Tailor Pharmacotherapy in Bipolar Disorder
- Abnormalities of Cortical Thickness in Bipolar Disorder With Auditory Hallucinations
- Prevalence of ADHD Relatively Stable Over Time Despite Increase in Diagnoses
- Prevalence of Major Depressive Disorder Remains High In US Population
- The Way to the Head May Be Through the Gut: Probiotics for Depression
- Suicide-Screening Toolkit Can Help Identify Youths at High Risk for Suicide
- Agoraphobia: An Evolving Understanding of Definitions and Treatment
- Parental Pressure to Diet Linked With Long-term Harm in Adolescents
- Does Access to Medical Cannabis Reduce Risk for Opioid Abuse?
- Evidence of Methylphenidate Abuse: Characterizing Patterns of Use in Pediatric and Adult Populations
- Intranasal Oxytocin Reduces Negative Effects, Improves Cognitive Function in Schizophrenia
- Most Patients Comfortable With Clinicians Asking About Sexual Orientation
- Peer-to-Peer Depression Awareness Program May Be Beneficial
- Examining Rates of Long-term Opioid Use in Youth With Psychiatric Disorders